1. Show article details.

    Smith & Wesson shares shoot up after earnings beat, outlook

    MarketWatch – 5:08 PM ET 03/03/2015

    By Wallace Witkowski and Sue Chang, MarketWatch. TiVo (TIVO) shares also rally on subscription growth. SAN FRANCISCO-- Shares of Smith& Wesson Holding Co. rallied in the extended session Tuesday after the gun maker's quarterly earnings and outlook topped Wall Street estimates.

  2. Show article details.

    MARKET SNAPSHOT: U.S. Stocks Retreat From Records; Car Sales Sputter

    DJ Business News – 4:36 PM ET 03/03/2015

    By Anora Mahmudova and Victor Reklaitis, MarketWatch. Monthly car sales slow to 10- month low in February. NEW YORK-- U.S. stocks declined on Tuesday, retreating from all-time highs and the psychologically significant 5,000 level for the Nasdaq reached on Monday.

  3. Show article details.

    U.S. stocks retreat from records; car sales sputter

    MarketWatch – 4:35 PM ET 03/03/2015

    By Anora Mahmudova and Victor Reklaitis, MarketWatch. Monthly car sales slow to 10- month low in February. NEW YORK-- U.S. stocks declined on Tuesday, retreating from all-time highs and the psychologically significant 5,000 level for the Nasdaq reached on Monday.

  4. Show article details.

    US STOCKS-Wall St falls from records, led by technology stocks

    Reuters – 4:33 PM ET 03/03/2015

    * Auto sales fall short of expectations. * Netanyahu warns Obama against Iran deal. * Technology stocks fall after Nasdaq milestone. * Indexes off: Dow 0.47 pct, S&P 0.45 pct, Nasdaq 0.56 pct. By Sinead Carew. U.S. stocks finished down on Tuesday, a day after the S&P and Dow hit records, and the Nasdaq retreated with technology stocks.

  5. Show article details.

    US STOCKS-Wall St falls from latest records after soft auto sales

    Reuters – 2:36 PM ET 03/03/2015

    * Auto sales fall short of expectations. * Netanyahu warns Obama against Iran deal. * Technology stocks fall after Nasdaq milestone. * Indexes off: Dow 0.45 pct, S&P 0.48 pct, Nasdaq 0.64 pct. By Sinead Carew. U.S. stocks fell on Tuesday, a day after S&P and Dow hit records and Nasdaq retreated after hitting a 15-year milestone after soft car sales data and Iran commentary worried some investors.

  6. Show article details.

    US STOCKS-Wall St falls from latest records; auto sales soft

    Reuters – 11:42 AM ET 03/03/2015

    * Auto sales fall short of expectations. * Best Buy (BBY) climbs after results. * Citigroup (C) to sell OneMain Financial to Springleaf Holdings (LEAF). * Indexes off: Dow 0.7 pct, S&P 0.8 pct, Nasdaq 0.9 pct. By Chuck Mikolajczak. U.S. stocks fell on Tuesday, as the Dow and S&P retreated from their latest records and the Nasdaq dipped below 5,000 after scaling the milestone level for the first time in 15 years.

  7. Show article details.

    US STOCKS-Wall St slips from latest records; Nasdaq below 5,000

    Reuters – 9:58 AM ET 03/03/2015

    * Auto sales fall short of expectations. * Best Buy (BBY) climbs after results. * Citigroup (C) to sell OneMain Financial to Springleaf Holdings (LEAF). * Indexes off: Dow 0.35 pct, S&P 0.41 pct, Nasdaq 0.44 pct. By Chuck Mikolajczak. U.S. stocks edged lower shortly after the open on Tuesday in the wake of the latest records for the Dow and S&P and the Nasdaq scaling the 5,000 mark for the first time in 15 years.

  8. Show article details.

    REFILE-US STOCKS-Wall St to dip at open after latest records, Nasdaq 5,000

    Reuters – 9:00 AM ET 03/03/2015

    * Auto sales expected throughout session. * Best Buy (BBY) climbs in premarket after results. * Citigroup (C) to sell OneMain Financial to Springleaf Holdings (LEAF). * Futures off: Dow 38 pts, S&P 5.75 pts, Nasdaq 9.25 pts. By Chuck Mikolajczak.

  9. Show article details.

    Mylan N.V. and Mylan Inc. Announce Commencement of Consent Solicitations for Mylan Inc.'s Notes

    PR Newswire – 8:55 AM ET 03/03/2015

    POTTERS BAR, England, and PITTSBURGH, March 3, 2015 Mylan N.V. (MYL) and Mylan Inc. today announced the commencement of consent solicitations relating to Mylan's 3.750% Cash Convertible Notes due 2015, 7.875% Senior Notes due 2020, 3.125% Senior Notes due 2023, 1.800% Senior Notes due 2016, 2.600% Senior Notes due 2018, 1.350% Senior Notes due 2016, 2.550% Senior Notes due 2019, 4.200% Senior Notes d...

  10. Show article details.

    Mylan still on the prowl for deals, perhaps one by end 2015

    Reuters – 7:23 PM ET 03/02/2015

    U.S. generic drug maker Mylan Inc (MYL) is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' (ABT) non-U.S. businesses just last week. Chief Executive Heather Bresch, on a call after the company posted fourth-quarter results on Monday, raised the prospect of another "material transaction" by the end of 2015.

  11. Show article details.

    Updates, advisories and surprises

    MarketWatch – 5:35 PM ET 03/02/2015

    Nabors shares down after Q4 loss, revenue miss. Nabors Industries Ltd. (NBR) said late Monday it lost $891 million in the fourth quarter, or $3.08 a share, compared with earnings of 50 cents a share a year ago. Adjusted for one-time items, the oil-field services company earned 33 cents a share in the quarter.

  12. Show article details.

    Mylan Posts Higher Profit and Sales

    DJ Business News – 5:13 PM ET 03/02/2015

    Mylan Inc. (MYL) said fourth-quarter profit rose 5% as the drug company said it had an "exceptional" quarter. For 2015, the company expects earnings excluding items of $4 to $4.30 a share on revenue of $9.6 billion to $10.1 billion. Analysts polled by Thomson Reuters expected $4.16 and $9.81 billion.

  13. Show article details.

    Mylan Files Annual Report on Form 10-K for Year Ended Dec. 31, 2014

    PR Newswire – 5:06 PM ET 03/02/2015

    POTTERS BAR, England and PITTSBURGH, March 2, 2015 Mylan N.V. and Mylan Inc. (MYL) today announced that Mylan Inc. (MYL) filed its Annual Report on Form 10-K for the year ended December 31, 2014 with the U.S. Securities and Exchange Commission on March 2, 2015.

  14. Show article details.

    Mylan fourth-quarter earnings in-line with Street

    MarketWatch – 4:36 PM ET 03/02/2015

    Mylan N.V. late Monday posted fourth-quarter earnings that were in-line with the Wall Street consensus. The generic drug maker reported adjusted fourth-quarter earnings of $1.05 a share on revenue of $2.08 billion. Analysts surveyed by FactSet estimated $1.05 a share on revenue of $2.07 billion.

  15. Show article details.

    Drugmaker Mylan's 4th-qtr profit rises on strong demand in N. America

    Reuters – 4:29 PM ET 03/02/2015

    Generic and specialty drugmaker Mylan Inc (MYL) reported a rise in quarterly profit and revenue, driven mainly by strong demand for its generics in North America. Net profit attributable to the company's common shareholders rose to $189.2 million, or 47 cents per share, in the fourth quarter ended Dec. 31, from $180.2 million, or 45 cents per share, a year earlier.

  16. Show article details.

    Mylan Fourth Quarter 2014 Adjusted Diluted EPS Increases 35% to $1.05 and Full Year Adjusted Diluted EPS Up 23% to $3.56

    PR Newswire – 4:11 PM ET 03/02/2015

    POTTERS BAR, England and PITTSBURGH Mylan N.V. and Mylan Inc. (MYL) today announced Mylan Inc.'s (MYL) financial results for the quarter and year ended December 31, 2014.

  17. Show article details.

    Jobs report key for investors in week ahead

    MarketWatch – 6:02 AM ET 03/01/2015

    Devil is in details of jobs report to push Fed to raise rates. SAN FRANCISCO-- Investor attention turns to the latest jobs report this week along with a slew of other economic data. Stocks were roughly flat last week but finished the month up with hefty gains.

  18. Show article details.

    MARKET SNAPSHOT: Jobs Report Key For Investors In Week Ahead

    DJ Business News – 6:02 AM ET 03/01/2015

    Devil is in details of jobs report to push Fed to raise rates. SAN FRANCISCO-- Investor attention turns to the latest jobs report this week along with a slew of other economic data. Stocks were roughly flat last week but finished the month up with hefty gains.

  19. Show article details.

    Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

    PR Newswire – 12:30 PM ET 02/27/2015

    POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015Mylan N.V. and Mylan Inc. (MYL) today announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Executive Chairman Robert J. Coury commented, "Today marks the beginning of the next exciting chapter of growth for Mylan.

  20. Show article details.

    Mylan Specialty to Present Findings from EpiPen4Schools® Program Survey

    PR Newswire – 10:45 AM ET 02/23/2015

    "Anaphylaxis is a serious and often unpredictable health problem in the U.S., particularly among children and adolescents," said Roger D. Graham, President, Mylan Specialty. "The EpiPen4Schools® survey results provide information regarding anaphylaxis management in schools, and it is our hope that it contributes to the growing body of data related to this important issue.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Mar
    2

    MYL Earnings Conference Call at 4:30 PM Listen

  • Mar
    2

    MYL announced Q4 earnings of $1.05 per share (vs. $1.040) at 3/2/2015 4:11:00 PM ET

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.